Literature DB >> 20297617

Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis.

Anita Gupta1, Benjamin Duckles, James Giordano.   

Abstract

Chemotherapy-induced and radiation-induced mucositis is a debilitating and often painful condition resulting in an inability to swallow, and thus inability to maintain adequate quality of life and overall functioning. To date, attempts on palliation of mucositis-related pain have primarily used topical anesthetic solutions and intravenous opioids; these approaches have achieved only limited success, particularly in oncology patients. The authors present a novel case of mucositis-related pain that is effectively treated with sublingual methadone. Sublingual methadone is an alternative to standard treatment options for mucositis-related pain and has unique pharmacokinetic and pharmacodynamic properties that make methadone a suitable agent for this pathology. These properties are addressed and discussed, as is the need for additional study to better understand the potential benefits, burdens, and risks that may be associated with this formulation of methadone when treating chemotherapy-induced and/or radiation therapy-induced mucositis in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20297617     DOI: 10.5055/jom.2010.0007

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  2 in total

Review 1.  [Topical pain therapy in oral mucositis: a systematic review].

Authors:  H Bornemann-Cimenti; S K Kobald; I S Szilagyi; A Sandner-Kiesling
Journal:  Schmerz       Date:  2013-06       Impact factor: 1.107

Review 2.  Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients.

Authors:  Deborah P Saunders; Joel B Epstein; Sharon Elad; Justin Allemano; Paolo Bossi; Marianne D van de Wetering; Nikhil G Rao; Carin Potting; Karis K Cheng; Annette Freidank; Michael T Brennan; Joanne Bowen; Kristopher Dennis; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-07-06       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.